The findings are notable in part because therapies have already been approved to target C5aR1 in other diseases.

Danny Rischin, MD, medical oncologist, clinician researcher, Peter McCallum Cancer Centre, discusses a novel adjuvant ...

In patients with cutaneous squamous cell carcinoma, Mohs surgery was associated with significantly better outcomes compared ...

Postoperative nivolumab added to standard-of-care adjuvant cisplatin radiotherapy “represents a potential new standard.” ...

The global burden of skin cancer is expected to grow as the population aged 65 years and older increases in the next 25 years.

Adjuvant cemiplimab improved DFS in patients with CSCC who had completed adjuvant radiotherapy and had a high risk of recurrence.

Additional data presented at ASCO highlights Libtayo’s ability to hold off recurrence of a type of skin cancer.